Eclat Health Is Said to Consider $300 Million India IPO
THE SO WHAT
A potential $300M India IPO for Eclat Health shows domestic markets are increasingly viable exits for healthtech and services firms, not just late-stage funding waypoints. Founders building in India should underwrite IPO as a realistic path earlier—cap table and governance discipline will matter sooner than in the old ‘wait for a global buyer’ model.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureDiscover how to take your startup from prototype to production at TechCrunch Disrupt 2026
The value here isn’t inspiration—it’s pattern-matching how Foxglove, MBRYONICS, and Bedrock Robotics handled the ugly middle from demo to deployment. If you’re going, show up with a specific bottleneck to interrogate, not a generic ‘scale’ question.
Startups & VentureEvvy raises $40M as it seeks to further women’s health research with vaginal microbiome data
Evvy’s $40M Series B for vaginal microbiome data is another data-network play in women’s health—own the hardest-to-replicate dataset, then layer AI on top. Healthcare operators should expect more specialized data platforms to sit between clinics and traditional EHRs.
Startups & VentureProfound raised $180m at a $1.8bn valuation to sell brands visibility in AI answers
A $180M Series D at a $1.8B valuation for Profound is a strong bet that ‘answer engine optimization’ becomes its own budget line—brands paying to show up in AI assistants’ responses, not just search. Marketing leaders should start asking where their content lands in model outputs and who owns that channel.
Startups & Venture4 days left to exhibit at TechCrunch Disrupt 2026
Exhibiting at Disrupt is less about foot traffic and more about compressing months of investor and partner meetings into three days. If you’re considering it, go only if you have a crisp story and at least one concrete deal type you want to leave with.